IRCCS Istituto Ortopedico Rizzoli, Laboratory of Experimental Oncology, via di Barbiano 1/10, 40136 Bologna, Italy.
IRCCS Istituto Ortopedico Rizzoli, Department of Pathology, via di Barbiano 1/10, 40136 Bologna, Italy.
Cells. 2020 Apr 14;9(4):968. doi: 10.3390/cells9040968.
Osteosarcoma, Ewing sarcoma and chondrosarcoma are rare diseases but the most common primary tumors of bone. The genes directly involved in the sarcomagenesis, tumor progression and treatment responsiveness are not completely defined for these tumors, and the powerful discovery of genetic analysis is highly warranted in the view of improving the therapy and cure of patients. The review summarizes recent advances concerning the molecular and genetic background of these three neoplasms and, of their most common variants, highlights the putative therapeutic targets and the clinical trials that are presently active, and notes the fundamental issues that remain unanswered. In the era of personalized medicine, the rarity of sarcomas may not be the major obstacle, provided that each patient is studied extensively according to a road map that combines emerging genomic and functional approaches toward the selection of novel therapeutic strategies.
骨肉瘤、尤文肉瘤和软骨肉瘤是罕见疾病,但却是最常见的原发性骨肿瘤。这些肿瘤的肉瘤发生、肿瘤进展和治疗反应性所涉及的直接基因尚未完全确定,鉴于提高患者的治疗和治愈率,非常有必要进行强大的遗传分析发现。本综述总结了这三种肿瘤及其最常见变异体的分子和遗传背景的最新进展,强调了潜在的治疗靶点和目前正在进行的临床试验,并指出了仍未解决的基本问题。在个性化医疗时代,肉瘤的罕见性可能不是主要障碍,只要根据路线图对每个患者进行广泛研究,该路线图结合了新兴的基因组和功能方法,以选择新的治疗策略。